Avidity Biosciences

San Diego, CA · Founded 2012 · Biotech · Acquired

Antibody Oligonucleotide Conjugates (AOC) platform for targeted RNA therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · aviditybiosciences.com

Sector
Biotech
Headquarters
San Diego, CA
Founded
2012
Latest Form D
$400M, Mar 2024
Total capital
$528M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$528M
4 Form D · last Mar 2024
31 months since last filing
Federal contracts
$200K
1 award · Health and Human S
Rank in Biotech#293 of 4373
Granted patents
20
20 pending · first 2024
Rank in peer group#32 of 1449

Capital timeline

201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $528M$200K1st Form D$9.1M2nd Form D$18M3rd Form D$101M4th Form D$400M
201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $528M$200K2nd Form D$18M4th Form D$400M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$400M
  • Private capital raisedForm D · SEC · 3rd filing$101M
  • Private capital raisedForm D · SEC · 2nd filing$18M
  • Private capital raisedForm D · SEC · 1st filing$9.1M
  • Federal contractHealth and Human S · Igf::ot::igf$200K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

5months

from Avidity Biosciences’s first federal award to its first private round.

First federal award · Sep 2013
Health and Human S · $200K
First Form D · Feb 2014
$9.1M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#32 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Arthur LevinExecutive OfficerNamed in SEC Form D filings
  • Carsten Michael BoessDirectorNamed in SEC Form D filings
  • Edward Michael KayeDirectorNamed in SEC Form D filings
  • Jean Michael KimDirectorNamed in SEC Form D filings
  • Michael Michael MacLeanExecutive OfficerNamed in SEC Form D filings
  • MICHAEL MARTINDirectorNamed in SEC Form D filings
Show all 17 people
  • Michael Martin PhD.DirectorNamed in SEC Form D filings
  • Noreen Michael HenigDirectorNamed in SEC Form D filings
  • P. Kent HawrylukExecutive OfficerNamed in SEC Form D filings
  • RODERICK WONGDirectorNamed in SEC Form D filings
  • Sarah BoyceExecutive Officer, DirectorNamed in SEC Form D filings
  • Tamar Michael ThompsonDirectorNamed in SEC Form D filings
  • Teresa Michael McCarthyExecutive OfficerNamed in SEC Form D filings
  • Todd BradyDirectorNamed in SEC Form D filings
  • TROY WILSONDirectorNamed in SEC Form D filings
  • Troy Wilson PhD., JDExecutive Officer, DirectorNamed in SEC Form D filings
  • W. Michael FlanaganExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 20 granted of 40
  • PendingNovel Preparation Of Oligonucleotide Conjugates Using Transition Metals Or Salts ThereofUSPTOApplication 19425930
  • PendingCompositions And Methods Of Treating Muscle DystrophyUSPTOApplication 19668501
  • PendingConjugate Compositions Comprising Phosphoryl Guanidine Linkages And Uses ThereofUSPTOApplication 19405243
Show all 40 patent records
  • Edesa Biotech, Inc.Similar federal contract value in Biotech · $214K in contracts
  • THE TINY CARGO COMPANYSimilar federal contract value in Biotech · $210K in contracts
  • Ursa AnalyticsSimilar federal contract value in Biotech · $205K in contracts
  • TARGEPEUTICS, INC.Similar federal contract value in Biotech · $200K in contracts
  • Celldex TherapeuticsSimilar federal contract value in Biotech · $199K in contracts
  • Aura BiosciencesSimilar federal contract value in Biotech · $198K in contracts

Press

1 article · matched on company name

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .